This company has been marked as potentially delisted and may not be actively trading. Capstar Special Purpose Acquisition (CPSR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CPSR vs. PTGX, MLTX, MTSR, CPRX, CRNX, VKTX, MOR, HCM, OGN, and AAPGShould you be buying Capstar Special Purpose Acquisition stock or one of its competitors? The main competitors of Capstar Special Purpose Acquisition include Protagonist Therapeutics (PTGX), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Catalyst Pharmaceuticals (CPRX), Crinetics Pharmaceuticals (CRNX), Viking Therapeutics (VKTX), MorphoSys (MOR), HUTCHMED (HCM), Organon & Co. (OGN), and Ascentage Pharma Group International (AAPG). These companies are all part of the "medical" sector. Capstar Special Purpose Acquisition vs. Its Competitors Protagonist Therapeutics MoonLake Immunotherapeutics Metsera Catalyst Pharmaceuticals Crinetics Pharmaceuticals Viking Therapeutics MorphoSys HUTCHMED Organon & Co. Ascentage Pharma Group International Protagonist Therapeutics (NASDAQ:PTGX) and Capstar Special Purpose Acquisition (NYSE:CPSR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations, community ranking and profitability. Do analysts rate PTGX or CPSR? Protagonist Therapeutics currently has a consensus target price of $65.44, indicating a potential upside of 16.95%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protagonist Therapeutics is more favorable than Capstar Special Purpose Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Capstar Special Purpose Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer PTGX or CPSR? Protagonist Therapeutics received 293 more outperform votes than Capstar Special Purpose Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformProtagonist TherapeuticsOutperform Votes29361.55% Underperform Votes18338.45% Capstar Special Purpose AcquisitionN/AN/A Which has stronger valuation & earnings, PTGX or CPSR? Capstar Special Purpose Acquisition has lower revenue, but higher earnings than Protagonist Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtagonist Therapeutics$207.80M16.69-$78.96M$0.7574.61Capstar Special Purpose AcquisitionN/AN/A-$15.30MN/AN/A Does the media favor PTGX or CPSR? In the previous week, Protagonist Therapeutics had 8 more articles in the media than Capstar Special Purpose Acquisition. MarketBeat recorded 8 mentions for Protagonist Therapeutics and 0 mentions for Capstar Special Purpose Acquisition. Protagonist Therapeutics' average media sentiment score of 0.76 beat Capstar Special Purpose Acquisition's score of 0.00 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Protagonist Therapeutics Positive Capstar Special Purpose Acquisition Neutral Do institutionals and insiders believe in PTGX or CPSR? 98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 64.9% of Capstar Special Purpose Acquisition shares are held by institutional investors. 4.9% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is PTGX or CPSR more profitable? Protagonist Therapeutics has a net margin of 52.76% compared to Capstar Special Purpose Acquisition's net margin of 0.00%. Protagonist Therapeutics' return on equity of 34.68% beat Capstar Special Purpose Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets Protagonist Therapeutics52.76% 34.68% 30.98% Capstar Special Purpose Acquisition N/A N/A N/A Which has more risk & volatility, PTGX or CPSR? Protagonist Therapeutics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500. Comparatively, Capstar Special Purpose Acquisition has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500. SummaryProtagonist Therapeutics beats Capstar Special Purpose Acquisition on 14 of the 15 factors compared between the two stocks. Get Capstar Special Purpose Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for CPSR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CPSR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPSR vs. The Competition Export to ExcelMetricCapstar Special Purpose AcquisitionPharmaceutical Preparations IndustryMedical SectorNYSE ExchangeMarket Cap$831.87M$6.88B$5.59B$19.66BDividend YieldN/A2.53%5.28%3.82%P/E RatioN/A8.5427.2035.09Price / SalesN/A262.76409.0842.90Price / CashN/A65.8538.3217.51Price / Book-20.436.526.974.79Net Income-$15.30M$143.48M$3.23B$1.02B Capstar Special Purpose Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPSRCapstar Special Purpose AcquisitionN/A$24.110.0%N/A+269.3%$831.87MN/A0.002PTGXProtagonist Therapeutics1.9781 of 5 stars$51.06+1.8%$65.44+28.2%+65.8%$3.16B$207.80M19.20120Insider TradeMLTXMoonLake Immunotherapeutics1.8922 of 5 stars$48.55+18.0%$78.71+62.1%+1.7%$3.11BN/A-37.642Analyst RevisionHigh Trading VolumeMTSRMetseraN/A$29.35+4.4%$47.00+60.1%N/A$3.08BN/A0.0081Analyst ForecastAnalyst RevisionGap DownCPRXCatalyst Pharmaceuticals4.7803 of 5 stars$24.91+0.0%$32.29+29.6%+57.2%$3.04B$534.65M21.1180Gap DownCRNXCrinetics Pharmaceuticals3.5619 of 5 stars$32.10+0.7%$74.56+132.3%-32.7%$3.01B$760K-8.61210Positive NewsAnalyst RevisionVKTXViking Therapeutics4.4061 of 5 stars$26.61+1.9%$87.15+227.5%-45.5%$2.99BN/A-26.6120News CoveragePositive NewsOptions VolumeAnalyst RevisionGap UpMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730HCMHUTCHMED1.4784 of 5 stars$14.70+8.1%$19.00+29.3%-1.1%$2.56B$630.20M0.001,760Upcoming EarningsOGNOrganon & Co.4.7935 of 5 stars$9.44+2.0%$18.00+90.8%-51.7%$2.45B$6.29B2.8310,000Trending NewsAAPGAscentage Pharma Group InternationalN/A$27.75+10.0%N/AN/A$2.42B$980.65M0.00600 Related Companies and Tools Related Companies Protagonist Therapeutics Competitors MoonLake Immunotherapeutics Competitors Metsera Competitors Catalyst Pharmaceuticals Competitors Crinetics Pharmaceuticals Competitors Viking Therapeutics Competitors MorphoSys Competitors HUTCHMED Competitors Organon & Co. Competitors Ascentage Pharma Group International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CPSR) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capstar Special Purpose Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capstar Special Purpose Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CPSR Stock Free CPSR Stock Alerts